SUPN
Supernus Pharmaceuticals Inc

2,384
Mkt Cap
$2.96B
Volume
840,147.00
52W High
$53.28
52W Low
$29.16
PE Ratio
46.17
SUPN Fundamentals
Price
$52.83
Prev Close
$52.02
Open
$52.30
50D MA
$46.82
Beta
0.56
Avg. Volume
689,652.52
EPS (Annual)
$1.32
P/B
2.79
Rev/Employee
$981,924.33
Loading...
Loading...
News
all
press releases
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·5d ago
News Placeholder
Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP
Zacks highlights United Natural Foods, Teladoc Health, Supernus, and BRP as strong relative price strength stocks positioned to outperform in volatile markets.
Zacks·11d ago
News Placeholder
Can 4 Relative Price Strength Stocks Defy Market Swings?
UNFI, TDOC, SUPN and BRP shine with strong relative price strength, earnings momentum, and analyst upgrades amid volatile markets.
Zacks·12d ago
News Placeholder
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·14d ago
News Placeholder
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.
Zacks·17d ago
News Placeholder
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·17d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
News Placeholder
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Zacks·1mo ago

Latest SUPN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.